VYNE Therapeutics Inc. Common Stock
Symbol: VYNE (NASDAQ)
1.05
▲ (5.00%) 0.050
Company Description:
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Key Stats
- Today's Open: $1.015
- Today's High: $1.09
- Today's Low: $1.015
- Today's Volume: 373
- Yesterday Close: $1
- Yesterday High: $1.15
- Yesterday Low: $0.998
- Yesterday Volume: 754.01K
- Last Min Volume: 0
- Last Min High: $1.054
- Last Min Low: $1.05
- Last Min VWAP: $0
Company Profile
- Name: VYNE Therapeutics Inc. Common Stock
- Website: https://www.vynetherapeutics.com
- Listed Date: 2018-01-25
- Location: BRIDGEWATER, NJ
- Market Status: Active
- CIK Number: 0001566044
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $21.00M
- Round Lot: 100
- Outstanding Shares: 16.66M
- Asset Type: CS
RECENT FILINGS FOR VYNE
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-05-19 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-08 | 10-Q | View |
| 2025-05-08 | 8-K | View |
| 2025-04-02 | 4 | View |
| 2025-04-02 | 4 | View |
| 2025-04-02 | 4 | View |
| 2025-04-02 | 4 | View |
| 2025-03-06 | 10-K | View |
| 2025-03-06 | 8-K | View |
| 2025-01-23 | 4 | View |
| 2025-01-23 | 4 | View |
| 2025-01-23 | 4 | View |
| 2025-01-23 | 4 | View |
| 2025-01-16 | 4 | View |
| 2025-01-13 | 8-K | View |
| 2025-01-02 | 4 | View |
| 2025-01-02 | 4 | View |
| 2025-01-02 | 4 | View |
Latest News on VYNE